T
THERAVECTYS
THERAVECTYS develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.
About THERAVECTYS
Theravectys operates in the biotech sector, focusing on the development of T cell vaccines using a proprietary lentiviral vector platform. The company targets both prophylactic and therapeutic vaccines, addressing critical unmet medical needs such as chronic infections and cancers, including the global HIV epidemic. By leveraging over 20 years of research, Theravectys aims to transform the field of vaccinology through strategic industrial partnerships and collaborations, including a joint laboratory with the Pasteur Institute. The business model centers on preclinical proof of concept across a broad range of indications, moving products through clinical stages and regulatory approval. Revenue is generated through global licensing and partnerships, positioning Theravectys as a potential game-changer in global health.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 69.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Tea, Wholesale, Intellectual Property, Biotechnology, Oncology, Immune System, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Feb 2021 | $18M | $73M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Jan 2015 | $2.1M | $8.4M | Bpifrance | — |
Growth signals
Latest recorded traffic for THERAVECTYS is 2.3K monthly website visits, up 167.4% over the last three months. THERAVECTYS's team declined 15.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
THERAVECTYS in the Paris ecosystem
The THERAVECTYS office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- JPJohn PIETERS
Philippe ODDO
Bpifrance
Other known investors1 additional known investor
Institut Pasteur
Source: Dealroom Talent Intelligence.
See THERAVECTYS’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










